TrialDiabetes care2021

The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.

Klara R Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.